Hepatitis C and general practice: The crucial role of primary care in stemming the epidemic

British Journal of General Practice

Volumn 55, Issue 513, 2005, Pages 259-260

  Budd, John ^a   Robertson, Roy ^b,c  

^a Muirhouse Medical Group   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Edinburgh Drug Addiction Study   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD TRANSFUSION; CHRONIC LIVER DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMMUNITY CARE; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DRUG ABUSE; EDITORIAL; EPIDEMIC; GENERAL PRACTICE; HEALTH EDUCATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MICROBIAL CONTAMINATION; NONHUMAN; PATIENT CARE; PATIENT RIGHT; PREVALENCE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PUBLIC HEALTH SERVICE; TREATMENT PLANNING; UNITED KINGDOM;

DISEASE OUTBREAKS; FAMILY PRACTICE; GREAT BRITAIN; HEPATITIS C; HUMANS;

EID: 17144367359     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (24)

1. Royal College of Physicians of Edinburgh. Consensus statement, consensus conference on hepatitis C, 21-22 April. Edinburgh: Royal College of Physicians of Edinburgh, 2004.
2. Johnson AM. AIDS epidemiology and natural history. In: Mindel A (ed). AIDS: a pocket book of diagnosis and management. London: Edward Arnold, 1990.
3. World Health Organisation. Weekly epidemiological record no 49. 2003; 78: 417-424.
4. Alter M J, Kruszon-Moran, D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
5. Health Protection Agency. Shooting up; infections among injecting drug users in the United Kingdom 2003. London: Health Protection Agency, 2004.
6. Edlin BR. Hepatitis C Prevention and treatment for substance users in the United States: acknowledging the elephant in the living room. Int J Drug Policy 2004; 15: 81-91.
7. Copeland L, Budd J, Robertson JR, Elton RA. Changing patterns in causes of death in a cohort of injecting drug users, 1980-2001. Arch Intern Med 2004; 164: 1214-1220.
8. Coutinho RA. HIV and hepatitis C among injecting drug users. BMJ 1998; 317: 424-425.
9. Hagan H, Thiede H, Weiss NS, et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Pub Health 2001; 91: 42-46.
10. Bresters D, Mauser-Bunschoten E, Reesink H, et al. Sexual transmission of hepatitis C virus. Lancet 1993; 342: 210-211.
11. Thomas SL, Newell ML, Peckham CS, et al. A review of hepatitis C virus (HCV) vertical transmission: risks to infants born to mothers with and without HCV viraemia or human immuno-deficiency virus infection. Int J Epidemiol 1998; 27: 108-117.
12. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001: 358: 958-965.
13. Jaeckel E, Cornberg M, Wedemeyer H. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-1457.
14. Veldt BJ, Soracco G, Boyer N, et al. Long-term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53: 1504-1508.
15. Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: an analytic model. Gut 2002; 50: 253-258.
16. Scottish Needs Assessment Programme. Hepatitis C. Glasgow: Office for Public Health In Scotland 2000.
17. Department of Health. Prevalence of HIV and hepatitis infections in the United Kingdom 2001. London: Department of Health, 2002.
18. Budd J, Copeland L, Elton R, Robertson JR. Hepatitis C infection in a cohort of injecting drug users. Past and present risk factors and the implications for educational and clinical management. Eur J Gen Pract 2002; 8: 95-100.
19. Poynard T, Ratziu V, Charlotte F, Goodman Z. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-739.
20. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816.
21. Tompkins CNE, Wright NMJ, Jones L. Impact of a positive hepatitis C diagnosis on homeless injecting drug users: a qualitative study. Br J Gen Pract 2005; 55: 263-268.
22. Department of Health. Hepatitis C - guidance for those working with drug users. London: HMSO, 2001.
23. Department of Health. Hepatitis C action plan for England London: Department of Health, 2004.
24. Department of Health. Hepatitis C strategy for England. London: Department of Health, 2002.